SCHEMBL16631293

SCHEMBL16631293

Cc1c[nH]c2nc(=S)n([C@@H]3O[C@H](CO)C(O)[C@@H]3O)cc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 1/20 0.42
LMNA P02545 2/20 0.40
MTOR P42345 2/20 0.40
THRB P10828 1/20 0.40
MDM2 Q00987 1/20 0.40
NCOA1 Q15788 1/20 0.40
NCOA3 Q9Y6Q9 1/20 0.40
GMNN O75496 1/20 0.40
ALDH1A1 P00352 1/20 0.40
TP53 P04637 1/20 0.40
NFKB1 P19838 1/20 0.40
DNMT1 P26358 1/20 0.40
THPO P40225 1/20 0.40
HTT P42858 1/20 0.40
RAB9A P51151 1/20 0.40
BLM P54132 1/20 0.40
HBB P68871 1/20 0.40
PMP22 Q01453 1/20 0.40
MAPT P10636 1/20 0.39
CDA P32320 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16631339 0.91 LMNA (0.42) CDK1LMNAMTORTHRBMDM2
SCHEMBL16631286 0.86 LMNA (0.43) LMNAMTORTHRBMDM2NCOA1
SCHEMBL18080288 0.86 LMNA (0.50) LMNAMTORTHRBMDM2NCOA1
SCHEMBL16631353 0.84 SLC28A1 (0.46) CDK1LMNAMTORTHRBMDM2
SCHEMBL16631277 0.83 LMNA (0.42) LMNAMTORTHRBMDM2NCOA1
SCHEMBL16631561 0.82 CDK1 (0.42) CDK1LMNAMTORTHRBMDM2
SCHEMBL28983213 0.80 TP53 (0.44) CDK1LMNAMTORTHRBMDM2
SCHEMBL15011346 0.80 TP53 (0.44) CDK1LMNAMTORTHRBMDM2
SCHEMBL15010790 0.80 ADORA3 (0.51) ADKADORA3ADORA1
SCHEMBL16631295 0.80 LMNA (0.48) LMNAMTORTHRBMDM2NCOA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2016-09-15 US disclosed
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2016-09-15 US disclosed
WO-2015051173-A2 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC (US) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF POLRMT, POLN, NSUN3 CDK1 3219/4885LMNA 776/4885MTOR 4754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.